These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36920288)

  • 1. Interdependence of SS18-SSX-driven YAP1 and β-Catenin Activation in Synovial Sarcoma.
    Isfort I; Berthold R; Heinst L; Wardelmann E; Larsson O; Trautmann M; Hartmann W
    Mol Cancer Res; 2023 Jun; 21(6):535-547. PubMed ID: 36920288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
    Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
    Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
    Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
    Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.
    McBride MJ; Pulice JL; Beird HC; Ingram DR; D'Avino AR; Shern JF; Charville GW; Hornick JL; Nakayama RT; Garcia-Rivera EM; Araujo DM; Wang WL; Tsai JW; Yeagley M; Wagner AJ; Futreal PA; Khan J; Lazar AJ; Kadoch C
    Cancer Cell; 2018 Jun; 33(6):1128-1141.e7. PubMed ID: 29861296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma.
    Raquib AR; Hofvander J; Ta M; Nielsen TO
    Appl Immunohistochem Mol Morphol; 2022 Sep; 30(8):531-539. PubMed ID: 35880992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Immunohistochemistry With Antibodies to SS18-SSX Chimeric Proteins and C-Terminus of SSX Protein for Synovial Sarcoma Differential Diagnosis.
    Lasota J; Chłopek M; Kaczorowski M; Natálie K; Ryś J; Kopczyński J; Sulaieva O; Michal M; Kruczak A; Harazin-Lechowska A; Szczepaniak M; Koshyk O; Hałoń A; Czapiewski P; Abdullaev Z; Kowalik A; Aldape KD; Michal M; Miettinen M
    Am J Surg Pathol; 2024 Jan; 48(1):97-105. PubMed ID: 37899499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.
    Yoneda Y; Ito S; Kunisada T; Morimoto Y; Kanzaki H; Yoshida A; Shimizu K; Ozaki T; Ouchida M
    PLoS One; 2013; 8(10):e77564. PubMed ID: 24130893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction.
    Li J; Mulvihill TS; Li L; Barrott JJ; Nelson ML; Wagner L; Lock IC; Pozner A; Lambert SL; Ozenberger BB; Ward MB; Grossmann AH; Liu T; Banito A; Cairns BR; Jones KB
    Cancer Discov; 2021 Oct; 11(10):2620-2637. PubMed ID: 34078620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SS18-SSX drives CREB activation in synovial sarcoma.
    Cyra M; Schulte M; Berthold R; Heinst L; Jansen EP; Grünewald I; Elges S; Larsson O; Schliemann C; Steinestel K; Hafner S; Simmet T; Wardelmann E; Kailayangiri S; Rossig C; Isfort I; Trautmann M; Hartmann W
    Cell Oncol (Dordr); 2022 Jun; 45(3):399-413. PubMed ID: 35556229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stability.
    Benabdallah NS; Dalal V; Scott RW; Marcous F; Sotiriou A; Kommoss FKF; Pejkovska A; Gaspar L; Wagner L; Sánchez-Rivera FJ; Ta M; Thornton S; Nielsen TO; Underhill TM; Banito A
    Nat Struct Mol Biol; 2023 Nov; 30(11):1640-1652. PubMed ID: 37735617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent TRPS1 expression in synovial sarcoma is associated with SS18-SSX fusion oncoprotein activity.
    Cloutier JM; Ingram DR; Wani K; Lazar AJ; Wang WL
    Hum Pathol; 2022 Dec; 130():88-94. PubMed ID: 36162599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.
    Zöllner SK; Rössig C; Toretsky JA
    Cancer Metastasis Rev; 2015 Sep; 34(3):417-28. PubMed ID: 26277104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes.
    El Beaino M; Rassy E; Hadid B; Araujo DM; Pavlidis N; Lin PP
    Curr Oncol Rep; 2020 Oct; 22(12):124. PubMed ID: 33025259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.
    Tamaki S; Fukuta M; Sekiguchi K; Jin Y; Nagata S; Hayakawa K; Hineno S; Okamoto T; Watanabe M; Woltjen K; Ikeya M; Kato T; Toguchida J
    PLoS One; 2015; 10(11):e0142991. PubMed ID: 26571495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma.
    Kadoch C; Crabtree GR
    Cell; 2013 Mar; 153(1):71-85. PubMed ID: 23540691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular detection of SS18-SSX fusion gene transcripts by cRNA in situ hybridization in synovial sarcoma using formalin-fixed, paraffin-embedded tumor tissue specimens.
    Kanemitsu S; Hisaoka M; Shimajiri S; Matsuyama A; Hashimoto H
    Diagn Mol Pathol; 2007 Mar; 16(1):9-17. PubMed ID: 17471153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.
    Carmody Soni EE; Schlottman S; Erkizan HV; Uren A; Toretsky JA
    Clin Orthop Relat Res; 2014 Mar; 472(3):874-82. PubMed ID: 23716114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.
    Brien GL; Remillard D; Shi J; Hemming ML; Chabon J; Wynne K; Dillon ET; Cagney G; Van Mierlo G; Baltissen MP; Vermeulen M; Qi J; Fröhling S; Gray NS; Bradner JE; Vakoc CR; Armstrong SA
    Elife; 2018 Nov; 7():. PubMed ID: 30431433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When used together SS18-SSX fusion-specific and SSX C-terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases.
    Zaborowski M; Vargas AC; Pulvers J; Clarkson A; de Guzman D; Sioson L; Maclean F; Chou A; Gill AJ
    Histopathology; 2020 Oct; 77(4):588-600. PubMed ID: 32559341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma.
    Cironi L; Petricevic T; Fernandes Vieira V; Provero P; Fusco C; Cornaz S; Fregni G; Letovanec I; Aguet M; Stamenkovic I
    Sci Rep; 2016 Feb; 6():22113. PubMed ID: 26905812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.